# 1. Financial Performance ## A. Key Figures * **Q3 FY26 Income:** **₹175 Cr** consolidated (+64%) · **₹113 Cr** regulated (+5%) · **₹38 Cr** emerging (+5%) * **9M FY26 Income:** **₹474 Cr** consolidated (+65%) * **Q3 EBITDA:** **₹54 Cr** (+86%) · **EBITDA Margin:** 30.9% (+360 bps YoY, +30 bps QoQ) * **9M EBITDA:** **₹138 Cr** (+87%) · **EBITDA Margin:** 29% (+340 bps) * **9M PAT:** **₹84 Cr** (>2x YoY) · **PAT Margin:** 17.7% (+350 bps) * **9M Operating Cash Flow:** **₹51 Cr** (significant improvement) ## B. Revenue Growth * **Broad-Based Expansion:** Robust top-line growth across both regulated and emerging markets, with consolidated revenue surging by 64% in Q3 and 65% for nine months. * **Cost Discipline:** Sharp decline in other expenses to **₹22 Cr** in Q3 driven by rationalization and consolidation, despite ongoing US plant expansion. ## C. Profitability Trends * **Margin Acceleration:** EBITDA margin expanded significantly in Q3 to 9%, reflecting strong operating leverage and cost control, even as PAT margin tripled to 7% over nine months. * **Sustained Earnings Growth:** Bottom-line growth of ~85% in Q3 aligns with EBITDA momentum, underscoring high incremental profitability. ## D. Cash Flow Strength * **Cash Flow Momentum:** Operating cash flow on a clear upward trend, supported by improved EBITDA conversion and disciplined working capital management. * **Working Capital Profile:** Net working capital cycle remains stable at **90–94 days**, indicating consistent operational execution. ## E. Balance Sheet Position * **Capital Allocation Clarity:** IPO proceeds largely ring-fenced for Atlanta facility; cash balance constrained post-**Apnar acquisition**, justifying promoter warrant issuance. --- # 2. Product Portfolio & Approvals ## A. Key Figures * **Approved ANDAs:** **46** as of Dec-2025 (+~3x from 12 in Dec-2024) · **28** approved but not launched * **Regulatory Approvals:** **56** new products approved in Q3 · **450** total registered products (Dec-2025) ## B. ANDA Pipeline Progress * **Explosive Pipeline Growth:** Approved ANDA count nearly quadrupled year-on-year, reflecting accelerated regulatory success and strategic portfolio expansion. * **Dual-Metric Transparency:** Management now emphasizes both ANDA count and individual strengths, as each strength varies meaningfully in margin, market focus, and commercial potential. * **Robust Future Launch Visibility:** 28 approved ANDAs and 22 in-development molecules (including **22 proprietary products** in regulated markets) set foundation for multi-year growth. ## C. Product Launches * **Accelerated Launch Cadence:** 18 of 46 approved ANDAs already commercialized; company targets **1–2 organic launches per quarter** and a broader pace of **3–5 total launches per quarter** over the next 6–8 quarters. * **Acquired Portfolio Monetization:** Four acquired ANDAs launched to date; **28 approved but unlaunched products** from acquisition to roll out over next 6–8 quarters, de-risking near-term growth. * **Organic Momentum:** Deferiprone—organically developed and partnered with Dr. Reddy—successfully launched in current quarter, validating internal R&D capability. ## D. Regulatory Approvals * **Sustained Approval Velocity:** 56 new product approvals in Q3 alone, with majority expected to commercialize in the near term, particularly in emerging markets. * **Deep Future Pipeline:** Over **850 products currently under registration**, signaling continued regulatory momentum beyond current approved portfolio. ## E. Control Substances * **High-Margin Niche Segment:** Control substances represent a **15%–20% revenue contribution** and carry inherently **higher margins**; two new product launches planned for FY '27. * **Growing Commercial Focus:** Management expects control substance segment to gain **meaningful traction** in the coming years. --- # 3. Segment & Revenue Mix ## A. Key Figures * **Regulated Markets Revenue:** ₹310 Cr 9MFY26 (+71%) * **Emerging Markets Revenue:** ₹99 Cr 9MFY26 (+17%) · **Q3 Revenue** (+48% YoY) * Branded Generics Revenue (India): ₹31 Cr 9MFY26 (+7x YoY) · **Q3 Revenue** (₹10.5 Cr, +6x YoY) ## B. Regulated Markets * **Dominant Growth Engine:** Regulated markets remain the largest revenue segment with robust momentum, driven by portfolio expansion, new customer acquisition, and long-term CDMO-CMO contracts ensuring visibility. * **Favorable Mix Shift:** Revenue mix is shifting toward higher-margin own products (ANDA), projected to reach **60% of regulated revenue** by year-end, enhancing profitability outlook. ## C. Emerging Markets * **Profitability Inflection:** Emerging markets achieved highest-ever quarterly financials and turned cash-flow positive, with EBITDA margins now in the **mid-teens range** and expected to sustain or improve. * **Growth Catalysts:** Strong performance fueled by commercialization of previously approved products, **56 recent product registrations**, and a strategic pivot to mixed molecules and premium pricing models. * **Export Expansion:** Dollar-denominated export revenue is rising significantly and expected to grow further over the next four to six quarters, supported by pursuit of **PIC/S approval** at Chhatral facility. ## D. Branded Generics * **Hypergrowth Trajectory:** India’s branded generics business is scaling rapidly with over 7x nine-month revenue growth, contributing meaningfully to segment diversification and overall top-line strength. ## E. CDMO/CMO Business * **Margin Differential:** CDMO/CMO gross margins are **4–6 percentage points lower** than own products, though US-regulated segment maintains strong **40% EBITDA margins** overall. * **Contractual Revenue Model:** All revenue streams—own products, CDMO, CMO—are governed by binding partner contracts, including one-time fees, licensing, and profit-sharing arrangements, particularly for government-accessed controlled substances. --- # 4. Manufacturing & Capacity ## A. Key Figures * US Capacity Expansion: 1 billion to 2 billion tablets (doubling) (by next year) * **Capex Guidance:** **₹50–100 Cr** (next 2–3 years) * **Stock in Trade Purchase:** **₹11 Cr to ₹37 Cr** (significant increase) ## B. US Facility Expansion * **Rapid Scalability:** New US facility features expansion-ready infrastructure and multiple clean rooms, enabling immediate access to regulated markets in the UK and Canada. * **Capacity Doubling:** Atlanta Oral Solid Facility expansion on track to double output by next year, supporting higher-margin product focus. ## C. India Production Shift * **Strategic CMO Transition:** Shift to domestic CMO model in India across four locations—including Apnar—drives higher reported inventory purchases due to outsourced production accounting. * **Margin Optimization:** Low-margin products relocated to Apnar in India, freeing up US capacity for **higher-margin offerings** and improving portfolio profitability. ## D. Apnar Integration * **Non-Additive Synergies:** Integration benefits are structural rather than linear, with production shifts creating operational efficiencies that make financial impact **"not one plus one equals two"**. ## E. Utilization Efficiency * **Lean Manufacturing Model:** Production only against confirmed orders with **pre-sold capacity** ensures minimal inventory—**≤15 days of FG**—and avoids write-offs from contract failures. * **Geographic Diversification:** Multi-location manufacturing enhances agility, accelerates launches, and strengthens CDMO/CMO competitiveness with **cost advantages across facilities**. --- # 5. M&A & Strategic Growth ## A. Key Figures * **Apnar Revenue Contribution:** **₹120–150 Cr** expected from consolidation * **Pipeline Value:** **$16–18 Mn** revenue from five approved ANDAs over 12–15 months ## B. Apnar Acquisition * **Strategic Platform Expansion:** Acquisition of 75% stake in US FDA-, UK MHRA-, and Health Canada-approved facility establishes a key offshore manufacturing and regulatory foothold. * **Revenue Synergy & Flexibility:** Adds five approved ANDAs and enables selective shift of US production to India, enhancing cost efficiency and supply resilience. * **Path to Full Control:** Remaining 25% stake expected to be acquired by Q2 FY27, signaling long-term commitment. ## C. Zoraya Pharmaceuticals * **US Commercialization Push:** Launch of Zoraya Pharmaceuticals strengthens direct presence in the US market, enabling end-to-end control over marketing and distribution of strategic products. --- # 6. Pricing & Demand Trends ## A. Key Figures * **Per Unit Price (Emerging Markets):** **~₹2** (significant improvement) ## B. Unit Price Movement * **Pricing Power:** Per unit pricing in emerging markets shows marked recovery, approaching **₹2**, reflecting stronger demand or improved product mix. --- # 7. Risks & Regulatory Factors ## A. Contract Execution Risk * **No Material Contract Disputes:** Management confirmed no historical contract disputes or failures resulting in inventory issues or write-offs. --- # 8. Guidance & Outlook ## A. Key Figures * **FY26 Revenue Growth Target:** **50%** YoY · **PAT Growth Target:** **100%** YoY * **EBITDA Margin:** **~30%** projected for FY26 (blended) vs. 29% prior * **Apnar Pharma Revenue (FY27):** **₹120–150 Cr** expected * **Branded Generics Revenue:** **₹40–50 Cr** this year · **>₹80 Cr** projected next year * **Emerging Markets Revenue (FY27):** **₹170–180 Cr** expected * **Emerging Markets EBITDA Margin:** **18–22%** projected by FY27, peaking at **20%** * **US Business Sustainable EBITDA Margin:** **~40%**, with **~1 pp** improvement potential ## B. FY26 Growth Targets * **Guidance Confirmed:** FY26 targets remain unchanged despite stronger quarterly run rate, reflecting management’s conservative stance. * **Performance Tracking Ahead:** Nine-month results are in line or slightly ahead of plan, with bottom-line outperformance and Q4 expected to be seasonally stronger. * **Sustainable Growth Focus:** Emphasis on building durable models in regulated and emerging markets to maintain profitable momentum across cycles. ## C. FY27 Revenue Projections * **Apnar to Drive Incremental Growth:** Facility turning cash flow positive this quarter; three product launches underpin FY27 revenue contribution. * **Branded Generics & Emerging Markets Scaling:** Branded generics set for **>100% revenue growth** next year; emerging markets on track for near-term scale at **₹170–180 Cr**. ## D. Margin Expectations * **Blended Margin Expansion:** EBITDA margin expected to improve to ~30% in FY26, supported by product mix and operational leverage. * **US Margin Resilience:** Sustainable margin of ~40% expected, with incremental gains from higher-margin own products. * **Emerging Markets Margin Trajectory:** Margins set for **significant year-on-year improvement**, with structural uplift expected through scale and optimization. * **PAT Growth Moderation Expected:** 100% PAT growth unlikely in FY27 due to tougher base; profitability expected to stabilize at **₹100–115 Cr** on **₹650 Cr PAT**.